Search research articles
Contact Us
Filters
Showing results (41-50 of 67) with videos related to
Page
of 7
Sort By:
AIDS (London, England)
|
November 5, 2013
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection
Maria C Puertas, Marta Massanella, Josep M Llibre, et al.
The Journal of Antimicrobial Chemotherapy
|
March 20, 2016
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
Lorna Leal, Agathe León, Berta Torres, et al.
The Journal of Antimicrobial Chemotherapy
|
March 20, 2016
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
Lorna Leal, Agathe León, Berta Torres, et al.
Journal of the International AIDS Society
|
November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
Daniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.
Nature Medicine
|
March 16, 2010
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
Maria J Buzón, Marta Massanella, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 19, 2021
Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin
José L Blanco, Irene Fuertes, Jordi Bosch, et al.
Antiviral Therapy
|
February 1, 2012
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study
Josep M Llibre, Maria J Buzón, Marta Massanella, et al.
Antiviral Therapy
|
June 26, 2014
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir
José L Blanco, Ana Gonzalez-Cordón, Josep M Llibre, et al.
AIDS (London, England)
|
August 19, 2004
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
Montserrat Laguno, Javier Murillas, José Luis Blanco, et al.
The Journal of Infectious Diseases
|
January 15, 2011
A therapeutic dendritic cell-based vaccine for HIV-1 infection
Felipe García, Núria Climent, Lambert Assoumou, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 67) with videos related to
Sort By:
Page
of 7
AIDS (London, England)
|
November 5, 2013
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection
Maria C Puertas, Marta Massanella, Josep M Llibre, et al.
The Journal of Antimicrobial Chemotherapy
|
March 20, 2016
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
Lorna Leal, Agathe León, Berta Torres, et al.
The Journal of Antimicrobial Chemotherapy
|
March 20, 2016
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
Lorna Leal, Agathe León, Berta Torres, et al.
Journal of the International AIDS Society
|
November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
Daniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.
Nature Medicine
|
March 16, 2010
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
Maria J Buzón, Marta Massanella, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 19, 2021
Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin
José L Blanco, Irene Fuertes, Jordi Bosch, et al.
Antiviral Therapy
|
February 1, 2012
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study
Josep M Llibre, Maria J Buzón, Marta Massanella, et al.
Antiviral Therapy
|
June 26, 2014
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir
José L Blanco, Ana Gonzalez-Cordón, Josep M Llibre, et al.
AIDS (London, England)
|
August 19, 2004
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
Montserrat Laguno, Javier Murillas, José Luis Blanco, et al.
The Journal of Infectious Diseases
|
January 15, 2011
A therapeutic dendritic cell-based vaccine for HIV-1 infection
Felipe García, Núria Climent, Lambert Assoumou, et al.
Page
of 7